Joop D Lefrandt

Joop D Lefrandt is an active researcher specializing in oncology and endocrinology, with a focus on late effects of cancer treatments, cardiovascular risks in cancer survivors, and metabolic disorders. His work contributes to UN Sustainable Development Goals related to good health and well-being. Collaborations span international teams addressing cancer survivorship and guideline harmonization.

Key research interests include: (1) Cardiovascular outcomes in testicular cancer survivors treated with cisplatin-based chemotherapy; (2) Metabolic syndrome surveillance in pediatric and young adult cancer survivors; (3) Thyroid hormone fluctuations during thyroid carcinoma treatment. He has developed clinical tools like vascular fingerprinting for risk stratification.

Recent publications emphasize translational research with implications for clinical guidelines and survivorship care. His work integrates molecular biomarkers (e.g., telomere length) with epidemiological studies to improve long-term patient outcomes.

He has supervised three research projects and contributed to high-impact journals such as the European Journal of Endocrinology and Journal of Clinical Oncology. Active collaborations include institutions globally, focusing on multidisciplinary approaches to cancer-related comorbidities.